227 related articles for article (PubMed ID: 32885559)
1. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Ryom L; Cotter A; De Miguel R; Béguelin C; Podlekareva D; Arribas JR; Marzolini C; Mallon P; Rauch A; Kirk O; Molina JM; Guaraldi G; Winston A; Bhagani S; Cinque P; Kowalska JD; Collins S; Battegay M;
HIV Med; 2020 Nov; 21(10):617-624. PubMed ID: 32885559
[TBL] [Abstract][Full Text] [Related]
2. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni J; Levi L; Alagaratnam J; Van Bremen K; Mastrangelo A; Waalewijn H; Molina JM; Guaraldi G; Winston A; Boesecke C; Cinque P; Bamford A; Calmy A; Marzolini C; Martínez E; Oprea C; Welch S; Koval A; Mendao L; Rockstroh JK;
HIV Med; 2023 Nov; 24(11):1126-1136. PubMed ID: 37849432
[TBL] [Abstract][Full Text] [Related]
3. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
Ryom L; De Miguel R; Cotter AG; Podlekareva D; Beguelin C; Waalewijn H; Arribas JR; Mallon PWG; Marzolini C; Kirk O; Bamford A; Rauch A; Molina JM; Kowalska JD; Guaraldi G; Winston A; Boesecke C; Cinque P; Welch S; Collins S; Behrens GMN;
HIV Med; 2022 Sep; 23(8):849-858. PubMed ID: 35338549
[TBL] [Abstract][Full Text] [Related]
4. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.
Ryom L; Boesecke C; Bracchi M; Ambrosioni J; Pozniak A; Arribas J; Behrens G; Mallon P; Puoti M; Rauch A; Miro JM; Kirk O; Marzolini C; Lundgren JD; Battegay M;
HIV Med; 2018 May; 19(5):309-315. PubMed ID: 29493093
[TBL] [Abstract][Full Text] [Related]
5. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.
Ryom L; Boesecke C; Gisler V; Manzardo C; Rockstroh JK; Puoti M; Furrer H; Miro JM; Gatell JM; Pozniak A; Behrens G; Battegay M; Lundgren JD;
HIV Med; 2016 Feb; 17(2):83-8. PubMed ID: 26548563
[TBL] [Abstract][Full Text] [Related]
6. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
8. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
[TBL] [Abstract][Full Text] [Related]
10. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
11. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
14. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study: Can dual ART mitigate the risk of potential drug-drug interactions among PLWH under stable ART?
Inkaya AÇ; Balli FN; Kara E; Demirkan K; Ünal S
Turk J Med Sci; 2023; 53(5):1505-1511. PubMed ID: 38813033
[TBL] [Abstract][Full Text] [Related]
16. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir: first global approval.
Ballantyne AD; Perry CM
Drugs; 2013 Sep; 73(14):1627-37. PubMed ID: 24052331
[TBL] [Abstract][Full Text] [Related]
18. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis.
Mazzitelli M; Sasset L; Leoni D; Putaggio C; Cattelan AM
Medicine (Baltimore); 2021 Dec; 100(52):e28488. PubMed ID: 34967394
[TBL] [Abstract][Full Text] [Related]
19. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
[TBL] [Abstract][Full Text] [Related]
20. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
